TrialDiabetes care2022

Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.

Juan Pablo Frias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.